VitalHub Announces Licensing Deal with Royal Berkshire NHS Foundation Trust
TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a...
Year: 2021
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the...
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION,...
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be...
OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call...
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based...
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade...
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
LOVE Pharma Announces Debut of New Products, BLOOM™ and AURALIEF™
Emerging Sexual Health Wellness Brand Launches BLOOM™ (a Female Arousal Gel) and AURALIEF™ (a Cannabis-Infused Sublingual Strip)VANCOUVER, BC CANADA, Oct....
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at...
HCW Biologics Announces Appointment of Two New Members to Board of Directors
New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and GovernanceMIRAMAR, Fla., Oct. 27,...
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple...
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore,...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and...
Marrone Bio Innovations to Report Third Quarter 2021 Results on Wednesday, November 10 at 4:30 p.m. Eastern Time
DAVIS, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers...
Microbix Receives $2.7 Million from Exercise of Warrants
Further Capital to Assist with Increasing Capacity and EfficiencyMISSISSAUGA, Ontario, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:...
Sharps Compliance Reports Fiscal 2022 First Quarter Results
First quarter revenue of $13.9 million increased 6% from the prior yearRetail market billings increased 6% for the quarter Professional...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the...
